1. Search Result
Search Result
Results for "

73

" in MedChemExpress (MCE) Product Catalog:

247

Inhibitors & Agonists

4

Fluorescent Dye

1

Biochemical Assay Reagents

11

Peptides

10

Inhibitory Antibodies

24

Natural
Products

23

Recombinant Proteins

7

Isotope-Labeled Compounds

13

Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131967

    CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD<em>73</em>-IN-4
  • HY-N7181

    Pterosonin E

    Others Cancer
    7,3'-Dihydroxy-5'-methoxyisoflavone (Pterosonin E) is an arylcoumarin. 7,3'-Dihydroxy-5'-methoxyisoflavone can be used for various biochemical studies .
    7,3'-Dihydroxy-5'-methoxyisoflavone
  • HY-N7806

    Others Others
    7,3'-Di-O-Methylorobol is a flavone that can be isolated from Sophora japonica .
    7,3'-Di-O-Methylorobol
  • HY-152582

    Nucleoside Antimetabolite/Analog Others
    7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
    7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • HY-155279

    Fungal Infection
    Antifungal agent 73 (compound A32) is an antifungal agent for azole-resistant candidiasis. Antifungal agent 73 disrupts the fungal cell wall and cell membrane. Antifungal agent 73 shows potent in vivo antifungal activity against pathogenic fungi and fluconazole-resistant strains .
    Antifungal agent <em>73</em>
  • HY-143232

    Fungal Bacterial Infection Cancer
    Antibacterial agent 73 (compound 7a) is a potent antimicrobial agent. Antibacterial agent 73 exhibits very good antitubercular activity (MIC=0.65 µg/mL) against Mtb H37Rv. Antibacterial agent 73 shows good activity against fungal and bacterial. Antibacterial agent 73 also shows cytotoxicity in MCF-7 breast cancer cell lines, with IC50 of 8.20 μM .
    Antibacterial agent <em>73</em>
  • HY-122214
    AC-73
    3 Publications Verification

    Autophagy Cancer
    AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the CD147/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .
    AC-<em>73</em>
  • HY-144209

    CD73 Cancer
    CD73-IN-6 is a CD73 inhibitor extracted from patent WO2022007677A1 compound 2. CD73-IN-6 can be used for the research of cancer .
    CD<em>73</em>-IN-6
  • HY-147918

    DNA/RNA Synthesis Cancer
    Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
    Anticancer agent <em>73</em>
  • HY-108034

    Others Neurological Disease
    GET73 is a γ-hydroxybutyric acid (GHB) analog, a naturally occurring neurotransmitter. GET73 has anti-alcohol and anxiolytic properties. GET73 significantly affects glutamate transmission in the hippocampus .
    GET<em>73</em>
  • HY-147594

    CD73 Cancer
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
    CD<em>73</em>-IN-13
  • HY-147593

    CD73 Cancer
    CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD<em>73</em>-IN-12
  • HY-145334

    CD73 Cancer
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD<em>73</em>-IN-5
  • HY-152074

    CD73 Cancer
    D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD<em>73</em>-IN-14
  • HY-137246

    CD73 Cancer
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
    CD<em>73</em>-IN-3
  • HY-104028B

    Others Neurological Disease
    (S)-BAY 73-6691 is the isomer of BAY 73-6691 (HY-104028), and can be used as an experimental control. BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor .
    (S)-BAY <em>73</em>-6691
  • HY-147588

    CD73 Cancer
    CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
    CD<em>73</em>-IN-7
  • HY-147589

    CD73 Cancer
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
    CD<em>73</em>-IN-8
  • HY-147590

    CD73 Inflammation/Immunology
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
    CD<em>73</em>-IN-9
  • HY-147592

    CD73 Inflammation/Immunology Cancer
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
    CD<em>73</em>-IN-11
  • HY-147591

    CD73 Inflammation/Immunology Cancer
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
    CD<em>73</em>-IN-10
  • HY-131435

    CD73 Cancer
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM .
    CD<em>73</em>-IN-2
  • HY-104028
    BAY 73-6691
    1 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease
    BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor .
    BAY <em>73</em>-6691
  • HY-D0499

    Fluorescent Dye
    Pigment yellow 73 is a disazomethine dye with solid-state fluorescence.a biologically active chemical.
    Pigment yellow <em>73</em>
  • HY-103695

    CD73 Cancer
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
    CD<em>73</em>-IN-1
  • HY-D0515

    Fluorescent Dye
    Disperse red 73 is a red dye derived from anthraquinone. It is used in plastics, textiles and cosmetics.
    Disperse red <em>73</em>
  • HY-151286

    STAT Cancer
    Antitumor agent-73 is a Diosgenin (HY-N0177) derivative, which inhibits STAT3 signaling and activates Pdia3/ERp57 exogenously. Antitumor agent-73 shows potent anti-tumor activity against various cancer cell lines, 7.9-341.7-fold stronger than Diosgenin .
    Antitumor agent-<em>73</em>
  • HY-151882

    EGFR Cancer
    EGFR-IN-73 (Compound 3f) is a potent inhibitor for the most common EGFR mutation EGFR Del19 with an IC50 of 119 nM .
    EGFR-IN-<em>73</em>
  • HY-133118
    6RK73
    1 Publications Verification

    Deubiquitinase Cancer
    6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer .
    6RK<em>73</em>
  • HY-D0555

    Fluorescent Dye Others
    C.I. Disperse orange 73 is an orange-orange dye commonly used for fiber dyeing.
    C.I. Disperse orange <em>73</em>
  • HY-162111

    SARS-CoV Infection
    SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .
    SARS-CoV-2-IN-<em>73</em>
  • HY-118941

    Prostaglandin Receptor Cardiovascular Disease
    BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure .
    BAY <em>73</em>-1449
  • HY-157722

    17β-HSD Metabolic Disease
    HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-<em>73</em>
  • HY-104028A

    Phosphodiesterase (PDE) Neurological Disease
    BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.
    BAY <em>73</em>-6691 racemate
  • HY-101864
    Blarcamesine hydrochloride
    2 Publications Verification

    Anavex 2-73

    Sigma Receptor Neurological Disease Cancer
    Blarcamesine hydrochloride (Anavex 2-73) is a Sigma-1 Receptor agonist with an IC50 of 860 nM.
    Blarcamesine hydrochloride
  • HY-RS02310

    Small Interfering RNA (siRNA) Others

    CDC73 Human Pre-designed siRNA Set A contains three designed siRNAs for CDC73 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDC73 Human Pre-designed siRNA Set A
    CDC73 Human Pre-designed siRNA Set A
  • HY-RS14924

    Small Interfering RNA (siRNA) Others

    TP73 Human Pre-designed siRNA Set A contains three designed siRNAs for TP73 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TP73 Human Pre-designed siRNA Set A
    TP73 Human Pre-designed siRNA Set A
  • HY-RS15794

    Small Interfering RNA (siRNA) Others

    WDR73 Human Pre-designed siRNA Set A contains three designed siRNAs for WDR73 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WDR73 Human Pre-designed siRNA Set A
    WDR73 Human Pre-designed siRNA Set A
  • HY-12445
    Asnuciclib
    2 Publications Verification

    CDKI-73; LS-007

    CDK Apoptosis Inflammation/Immunology Cancer
    Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with Ki values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .
    Asnuciclib
  • HY-14758

    NG2-73

    GABA Receptor Neurological Disease
    Adipiplon (NG2-73) is a selective GABAA receptor positive allosteric modulator. Adipiplon is particularly useful in the research of a variety of central nervous system (CNS) disorders.
    Adipiplon
  • HY-13308
    Regorafenib Hydrochloride
    45+ Cited Publications

    BAY 73-4506 hydrochloride

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .
    Regorafenib Hydrochloride
  • HY-P3260

    CD73; 5′-NT

    Endogenous Metabolite Metabolic Disease
    5′-Nucleotidase, Microorganism (CD73) is an intrinsic membrane glycoprotein present as an ectoenzyme. 5′-Nucleotidase catalyzes hydrolysis of 5-nucleotides to their corresponding nucleosides .
    5′-Nucleotidase, Microorganism
  • HY-P99558

    GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX

    EGFR Cancer
    Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
    Timigutuzumab
  • HY-P4972

    Tau Protein Neurological Disease
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is aTau fragment.
    Tau Peptide (45-<em>73</em>) (Exon 2/Insert 1 Domain)
  • HY-10331
    Regorafenib
    45+ Cited Publications

    BAY 73-4506

    VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib
  • HY-10331A
    Regorafenib monohydrate
    45+ Cited Publications

    BAY 73-4506 monohydrate

    VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate
  • HY-10331B

    BAY 73-4506 mesylate

    VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie Cancer
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .
    Regorafenib mesylate
  • HY-10331S1

    BAY 73-4506-13C,d3

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib- 13C,d3 is the 13C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
    Regorafenib-13C,d3
  • HY-P99181

    CPI-006

    CD73 Infection Inflammation/Immunology
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells .
    Mupadolimab
  • HY-146759

    CD73 Cancer
    ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer .
    ZM514

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: